Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
1. A method of making a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin, the method comprising:
melting a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin;
adding colloidal silicon dioxide to the melted base to produce a batch, wherein adding the colloidal silicon dioxide to the melted base comprises mixing the colloidal silicon dioxide with the base to hydrate the colloidal silicon dioxide; and
adding hydrocortisone acetate to the batch, thereby producing a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin,
wherein the formulation comprises about 0.5% to about 5% by weight hydrocortisone acetate, about 0.1% to about 5% by weight colloidal silicon dioxide and the semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin.
2. A method of making a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin, the method comprising:
melting a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin using a hot stir plate and water bath;
adding colloidal silicon dioxide to the melted base to produce a batch, wherein adding the colloidal silicon dioxide to the melted base comprises mixing the colloidal silicon dioxide with the base to hydrate the colloidal silicon dioxide; and
adding hydrocortisone acetate to the batch, thereby producing a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin, wherein the formulation comprises about 0.5% to about 5% by weight hydrocortisone acetate, about 0.1% to about 5% by weight colloidal silicon dioxide and the semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin.
3. A method of making a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin, the method comprising:
melting a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin using low shear sweep or side scrape mixing, or a combination thereof;
adding colloidal silicon dioxide to the melted base to produce a batch, wherein adding the colloidal silicon dioxide to the melted base comprises mixing the colloidal silicon dioxide with the base to hydrate the colloidal silicon dioxide; and
adding hydrocortisone acetate to the batch, thereby producing a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin,
wherein the formulation comprises about 0.5% to about 5% by weight hydrocortisone acetate, about 0.1% to about 5% by weight colloidal silicon dioxide and the semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin.
4. The method of claim 1 , wherein the base is melted at a temperature between about 50° C. and about 60° C.
5. A method of making a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin, the method comprising:
melting a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin;
adding colloidal silicon dioxide to the melted base to produce a batch, wherein adding the colloidal silicon dioxide to the melted base comprises mixing the colloidal silicon dioxide with the base using a mesh to hydrate the colloidal silicon dioxide; and
adding hydrocortisone acetate to the batch, thereby producing a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin,
wherein the formulation comprises about 0.5% to about 5% by weight hydrocortisone acetate, about 0.1% to about 5% by weight colloidal silicon dioxide and the semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin.
6. The method of claim 5 , wherein the mesh is a square shape mesh.
7. The method of claim 5 , wherein the mixing is performed at a mixing speed of between about 3000 RPM and about 3500 RPM.
8. The method of claim 5 , wherein the mixing is maintained at a temperature of between about 50° C. and about 60° C.
9. A method of making a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin, the method comprising:
melting a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin;
adding colloidal silicon dioxide to the melted base to produce a batch, wherein adding the colloidal silicon dioxide to the melted base comprises mixing the colloidal silicon dioxide with the base to hydrate the colloidal silicon dioxide; and
adding hydrocortisone acetate to the batch by mixing using a homogenizer, thereby producing a formulation comprising hydrocortisone acetate, colloidal silicon dioxide, and a semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin,
wherein the formulation comprises about 0.5% to about 5% by weight hydrocortisone acetate, about 0.1% to about 5% by weight colloidal silicon dioxide and the semi-synthetic glyceride base comprising saturated C8-C18 triglyceride fatty acids and lecithin.
10. The method of claim 9 , wherein the homogenizer is set at between about 4000 RPM to about 4500 RPM.
11. The method of claim 9 , wherein the homogenizer is equipped with a square shape mesh.
12. The method of claim 9 , wherein the mixing is performed at a temperature of between about 50° C. and about 60° C.